I.

Baseline characteristics of patients before starting treatment

1. Baseline clinical data of patients
Treatment Treatment Test of Sig. crude Adjuste CI
naive experienced (p-value) d OD 95%
Age in years
(Mean ±SD)
Gender: n (%)
‒ Male
‒ Female
BMI: n (%)
‒ Underweight
‒ Normal
‒ Overweight
‒ Obese
‒ Extremely obese
Child Class: n (%)
‒ Class A
‒ Class B
‒ Class C
Arrhythmia by
ECG: n (%)
‒ Negative
‒ positive
Liver by US: n (%)
‒ No cirrhosis
‒ Cirrhosis
Spleen by US: n (%)
‒ Normal
‒ Large
Ascites by US: n (%)
‒ None 100 %
‒ Mild/moderate
‒ Severe
HCC by US: n (%)
‒ Negative 100 %
‒ Positive
Esophageal varices
by UGITE: n (%)
‒ None
‒ Grade 1
‒ Grade 2
‒ Grade 3/4 0%
BMI: body mass index, ECG: Electrocardiography, US: ultrasound, HCC: hepatocellular carcinoma,
UGITE: Upper Gastro-intestinal Tract Endoscopy
 2. Baseline laboratory and viral load data of patients:
Treatmen Treatme Test of crude Adjust CI
t naive nt Sig. (p- ed OD 95%
experienc value)
ed
Hemoglobin (g/dL)
WBC (x103
cells/mm3)
ANC (x103 cells/mm3)
Platelets (x103
cells/mm3)
INR
ALT (IU/L)
AST (IU/L)
Albumin (g/dL)
Bilirubin (mg/dL)
AFP (IU/L)
Urea (mg/dL)
Creatinine (mg/dL)
Creatinine clearance
(mL/min)
HCV-RNA Log10
(IU/mL)
Data are expressed as mean ± standard deviation, WBC: White blood cells, ANC:
Absolute neutrophilic count, INR: international normalized ratio, ALT: alanine
transaminase, AST: aspartate transaminase, AFP: alfa-fetoprotein, HCV: hepatitis C
virus, RNA: ribonucleic acid
 II. Follow-up characteristics of patients after 4 weeks of treatment
1. Clinical data of patients after 4 weeks of treatment
Treatment Treatment Test of Sig. crude Adjuste CI
naive experienced (p-value) d OD 95%
Child Class: n (%)
‒ Class A 32.7% 34.02% 1.5(.46) .45(.5) .58(.35) .19-1.9
‒ Class B 65.02% 61.82%
‒ Class C 4.16% 4.16%
Arrhythmia by ECG:
n (%)
‒ Negative
‒ positive
Ascites by US: n (%)
‒ None 100 %
‒ Mild/moderate
‒ Severe
HCC by US: n (%)
‒ Negative 48 % 50.2% .23(.63) .9(.58) .92(.67) .64-1.3
‒ Positive 52% 49.8%
Esophageal varices by
UGITE: n (%)
‒ None 100% 100%
‒ Grade 1
‒ Grade 2
‒ Grade 3/4
BMI: body mass index, ECG: Electrocardiography, US: ultrasound, HCC: hepatocellular carcinoma,
UGITE: Upper Gastro-intestinal Tract Endoscopy
 2. Laboratory data of patients after 4 weeks of treatment
Treatme Treatme Test of crude Adjust CI
nt naive nt Sig. (p- ed OD 95
experienc value) %
ed
Hemoglobin (g/dL) 9.4(.88) 9.45(.85) 1.07(.5 1.07(.5 .9-
5) 5) 1.3
WBC (x103 8.5(.89) 8.4(.85) .85(.11 .86(.17
cells/mm )3
) )
ANC (x103
cells/mm3)
Platelets (x103
cells/mm3)
INR
ALT (IU/L)
AST (IU/L)
Albumin (g/dL)
Bilirubin (mg/dL)
AFP (IU/L)
Urea (mg/dL)
Creatinine (mg/dL)
Creatinine clearance
(mL/min)
HCV-RNA Log10 by
PCR (IU/mL)
Data are expressed as mean ± standard deviation, WBC: White blood cells, ANC:
Absolute neutrophilic count, INR: international normalized ratio, ALT: alanine
transaminase, AST: aspartate transaminase, AFP: alfa-fetoprotein, HCV: hepatitis C
virus, RNA: ribonucleic acid
 3. Primary Efficacy and Safety Endpoints after 4 weeks of treatment

Treatment Treatment Test of Sig. crude Adjuste CI

naive experienced (p-value) d OD 95%
HCV-RNA by PCR: n (%)
‒ Negative
‒ Positive
Anemia: n (%)
Arrhythmia: n (%)
Hepatotoxicity: n (%)
HRS: n (%)
HCV: hepatitis C virus, RNA: ribonucleic acid, HRS: Hepatorenal syndrome